nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydroflumethiazide—SLC12A1—Cation-coupled Chloride cotransporters—SLC12A2—skin cancer	0.0716	0.273	CbGpPWpGaD
Hydroflumethiazide—SLC12A3—Cation-coupled Chloride cotransporters—SLC12A2—skin cancer	0.065	0.248	CbGpPWpGaD
Hydroflumethiazide—SLC12A1—appendage—skin cancer	0.0394	0.105	CbGeAlD
Hydroflumethiazide—ATP1A1—Preimplantation Embryo—PADI6—skin cancer	0.0363	0.139	CbGpPWpGaD
Hydroflumethiazide—KCNMA1—blood vessel—skin cancer	0.0199	0.0529	CbGeAlD
Hydroflumethiazide—CA1—nerve—skin cancer	0.0192	0.0512	CbGeAlD
Hydroflumethiazide—CA4—nerve—skin cancer	0.015	0.04	CbGeAlD
Hydroflumethiazide—Vasculitis—Vemurafenib—skin cancer	0.014	0.0385	CcSEcCtD
Hydroflumethiazide—ATP1A1—hair follicle—skin cancer	0.0136	0.0363	CbGeAlD
Hydroflumethiazide—ATP1A1—Preimplantation Embryo—NKX2-1—skin cancer	0.012	0.0457	CbGpPWpGaD
Hydroflumethiazide—Photosensitivity—Vemurafenib—skin cancer	0.0113	0.0311	CcSEcCtD
Hydroflumethiazide—SLC12A1—epithelium—skin cancer	0.0107	0.0284	CbGeAlD
Hydroflumethiazide—CA2—hair follicle—skin cancer	0.0104	0.0278	CbGeAlD
Hydroflumethiazide—SLC12A3—female reproductive system—skin cancer	0.0104	0.0277	CbGeAlD
Hydroflumethiazide—CA12—connective tissue—skin cancer	0.00976	0.026	CbGeAlD
Hydroflumethiazide—KCNMA1—epithelium—skin cancer	0.00966	0.0258	CbGeAlD
Hydroflumethiazide—CA9—female reproductive system—skin cancer	0.0093	0.0248	CbGeAlD
Hydroflumethiazide—Muscle spasms—Vismodegib—skin cancer	0.00929	0.0256	CcSEcCtD
Hydroflumethiazide—ATP1A1—nipple—skin cancer	0.00922	0.0246	CbGeAlD
Hydroflumethiazide—ATP1A1—neck—skin cancer	0.00912	0.0243	CbGeAlD
Hydroflumethiazide—SLC12A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—skin cancer	0.00888	0.0339	CbGpPWpGaD
Hydroflumethiazide—Purpura—Imiquimod—skin cancer	0.00877	0.0241	CcSEcCtD
Hydroflumethiazide—CA4—nipple—skin cancer	0.00852	0.0227	CbGeAlD
Hydroflumethiazide—CA4—neck—skin cancer	0.00843	0.0225	CbGeAlD
Hydroflumethiazide—SLC12A3—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—skin cancer	0.00807	0.0308	CbGpPWpGaD
Hydroflumethiazide—CA9—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.00794	0.0303	CbGpPWpGaD
Hydroflumethiazide—Photosensitivity reaction—Vemurafenib—skin cancer	0.00782	0.0215	CcSEcCtD
Hydroflumethiazide—Aplastic anaemia—Dactinomycin—skin cancer	0.00724	0.0199	CcSEcCtD
Hydroflumethiazide—CA5B—mammalian vulva—skin cancer	0.00721	0.0192	CbGeAlD
Hydroflumethiazide—KCNMA1—female reproductive system—skin cancer	0.00718	0.0191	CbGeAlD
Hydroflumethiazide—CA2—nipple—skin cancer	0.00707	0.0188	CbGeAlD
Hydroflumethiazide—CA2—neck—skin cancer	0.00699	0.0186	CbGeAlD
Hydroflumethiazide—CA12—female reproductive system—skin cancer	0.00688	0.0183	CbGeAlD
Hydroflumethiazide—Decreased appetite—Vismodegib—skin cancer	0.00685	0.0189	CcSEcCtD
Hydroflumethiazide—Constipation—Vismodegib—skin cancer	0.00674	0.0186	CcSEcCtD
Hydroflumethiazide—Photosensitivity reaction—Imiquimod—skin cancer	0.00667	0.0184	CcSEcCtD
Hydroflumethiazide—SLC12A1—head—skin cancer	0.00662	0.0176	CbGeAlD
Hydroflumethiazide—Aplastic anaemia—Temozolomide—skin cancer	0.00655	0.018	CcSEcCtD
Hydroflumethiazide—ATP1A1—connective tissue—skin cancer	0.00654	0.0174	CbGeAlD
Hydroflumethiazide—ATP1A1—epithelium—skin cancer	0.00621	0.0166	CbGeAlD
Hydroflumethiazide—CA5B—female reproductive system—skin cancer	0.00617	0.0165	CbGeAlD
Hydroflumethiazide—KCNMA1—head—skin cancer	0.006	0.016	CbGeAlD
Hydroflumethiazide—ATP1A1—skin of body—skin cancer	0.0059	0.0157	CbGeAlD
Hydroflumethiazide—CA12—head—skin cancer	0.00575	0.0153	CbGeAlD
Hydroflumethiazide—Vascular purpura—Temozolomide—skin cancer	0.00566	0.0156	CcSEcCtD
Hydroflumethiazide—Asthenia—Vismodegib—skin cancer	0.00566	0.0156	CcSEcCtD
Hydroflumethiazide—CA1—lymphoid tissue—skin cancer	0.00565	0.0151	CbGeAlD
Hydroflumethiazide—CA1—female reproductive system—skin cancer	0.00545	0.0145	CbGeAlD
Hydroflumethiazide—Diarrhoea—Vismodegib—skin cancer	0.00539	0.0149	CcSEcCtD
Hydroflumethiazide—ATP1A1—mammalian vulva—skin cancer	0.00538	0.0144	CbGeAlD
Hydroflumethiazide—Photosensitivity—Fluorouracil—skin cancer	0.00531	0.0146	CcSEcCtD
Hydroflumethiazide—Purpura—Temozolomide—skin cancer	0.00525	0.0145	CcSEcCtD
Hydroflumethiazide—CA5B—head—skin cancer	0.00516	0.0138	CbGeAlD
Hydroflumethiazide—Vomiting—Vismodegib—skin cancer	0.00501	0.0138	CcSEcCtD
Hydroflumethiazide—CA2—connective tissue—skin cancer	0.00501	0.0134	CbGeAlD
Hydroflumethiazide—Rash—Vismodegib—skin cancer	0.00497	0.0137	CcSEcCtD
Hydroflumethiazide—Dermatitis—Vismodegib—skin cancer	0.00497	0.0137	CcSEcCtD
Hydroflumethiazide—ATP1A1—lymphoid tissue—skin cancer	0.00478	0.0127	CbGeAlD
Hydroflumethiazide—CA2—epithelium—skin cancer	0.00476	0.0127	CbGeAlD
Hydroflumethiazide—Nausea—Vismodegib—skin cancer	0.00468	0.0129	CcSEcCtD
Hydroflumethiazide—Agitation—Imiquimod—skin cancer	0.00468	0.0129	CcSEcCtD
Hydroflumethiazide—ATP1A1—female reproductive system—skin cancer	0.00461	0.0123	CbGeAlD
Hydroflumethiazide—CA1—head—skin cancer	0.00456	0.0121	CbGeAlD
Hydroflumethiazide—CA2—skin of body—skin cancer	0.00452	0.0121	CbGeAlD
Hydroflumethiazide—CA4—female reproductive system—skin cancer	0.00426	0.0114	CbGeAlD
Hydroflumethiazide—Decreased appetite—Vemurafenib—skin cancer	0.00423	0.0117	CcSEcCtD
Hydroflumethiazide—KCNMA1—lymph node—skin cancer	0.0042	0.0112	CbGeAlD
Hydroflumethiazide—KCNMA1—Circadian rythm related genes—NKX2-1—skin cancer	0.0042	0.016	CbGpPWpGaD
Hydroflumethiazide—Constipation—Vemurafenib—skin cancer	0.00416	0.0115	CcSEcCtD
Hydroflumethiazide—CA2—mammalian vulva—skin cancer	0.00413	0.011	CbGeAlD
Hydroflumethiazide—Agranulocytosis—Dactinomycin—skin cancer	0.00403	0.0111	CcSEcCtD
Hydroflumethiazide—Photosensitivity reaction—Temozolomide—skin cancer	0.00399	0.011	CcSEcCtD
Hydroflumethiazide—SLC12A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00397	0.0152	CbGpPWpGaD
Hydroflumethiazide—Anorexia—Imiquimod—skin cancer	0.00396	0.0109	CcSEcCtD
Hydroflumethiazide—Hyperglycaemia—Temozolomide—skin cancer	0.00395	0.0109	CcSEcCtD
Hydroflumethiazide—ATP1A1—head—skin cancer	0.00385	0.0103	CbGeAlD
Hydroflumethiazide—Photosensitivity reaction—Fluorouracil—skin cancer	0.00368	0.0101	CcSEcCtD
Hydroflumethiazide—CA2—lymphoid tissue—skin cancer	0.00366	0.00977	CbGeAlD
Hydroflumethiazide—CA5B—lymph node—skin cancer	0.00361	0.00963	CbGeAlD
Hydroflumethiazide—Decreased appetite—Imiquimod—skin cancer	0.00361	0.00994	CcSEcCtD
Hydroflumethiazide—SLC12A3—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.0036	0.0138	CbGpPWpGaD
Hydroflumethiazide—Hypersensitivity—Vemurafenib—skin cancer	0.00359	0.00988	CcSEcCtD
Hydroflumethiazide—CA4—head—skin cancer	0.00356	0.00949	CbGeAlD
Hydroflumethiazide—CA2—female reproductive system—skin cancer	0.00353	0.00942	CbGeAlD
Hydroflumethiazide—Asthenia—Vemurafenib—skin cancer	0.00349	0.00962	CcSEcCtD
Hydroflumethiazide—Agranulocytosis—Fluorouracil—skin cancer	0.00336	0.00924	CcSEcCtD
Hydroflumethiazide—Diarrhoea—Vemurafenib—skin cancer	0.00333	0.00918	CcSEcCtD
Hydroflumethiazide—Urticaria—Imiquimod—skin cancer	0.0033	0.00909	CcSEcCtD
Hydroflumethiazide—Leukopenia—Bleomycin—skin cancer	0.00324	0.00891	CcSEcCtD
Hydroflumethiazide—Dizziness—Vemurafenib—skin cancer	0.00322	0.00887	CcSEcCtD
Hydroflumethiazide—CA1—lymph node—skin cancer	0.00319	0.0085	CbGeAlD
Hydroflumethiazide—Vomiting—Vemurafenib—skin cancer	0.0031	0.00853	CcSEcCtD
Hydroflumethiazide—Orthostatic hypotension—Docetaxel—skin cancer	0.00308	0.00847	CcSEcCtD
Hydroflumethiazide—Rash—Vemurafenib—skin cancer	0.00307	0.00846	CcSEcCtD
Hydroflumethiazide—Dermatitis—Vemurafenib—skin cancer	0.00307	0.00845	CcSEcCtD
Hydroflumethiazide—Hypersensitivity—Imiquimod—skin cancer	0.00306	0.00843	CcSEcCtD
Hydroflumethiazide—Headache—Vemurafenib—skin cancer	0.00305	0.0084	CcSEcCtD
Hydroflumethiazide—Cramp muscle—Docetaxel—skin cancer	0.00303	0.00835	CcSEcCtD
Hydroflumethiazide—Leukopenia—Dactinomycin—skin cancer	0.00302	0.00831	CcSEcCtD
Hydroflumethiazide—Asthenia—Imiquimod—skin cancer	0.00298	0.00821	CcSEcCtD
Hydroflumethiazide—CA2—head—skin cancer	0.00295	0.00787	CbGeAlD
Hydroflumethiazide—Nausea—Vemurafenib—skin cancer	0.00289	0.00797	CcSEcCtD
Hydroflumethiazide—Thrombocytopenia—Bleomycin—skin cancer	0.00289	0.00796	CcSEcCtD
Hydroflumethiazide—Diarrhoea—Imiquimod—skin cancer	0.00284	0.00783	CcSEcCtD
Hydroflumethiazide—Anorexia—Bleomycin—skin cancer	0.00281	0.00775	CcSEcCtD
Hydroflumethiazide—Agitation—Temozolomide—skin cancer	0.0028	0.00772	CcSEcCtD
Hydroflumethiazide—Dizziness—Imiquimod—skin cancer	0.00275	0.00756	CcSEcCtD
Hydroflumethiazide—Vertigo—Temozolomide—skin cancer	0.00274	0.00755	CcSEcCtD
Hydroflumethiazide—Leukopenia—Temozolomide—skin cancer	0.00273	0.00752	CcSEcCtD
Hydroflumethiazide—ATP1A1—lymph node—skin cancer	0.0027	0.00719	CbGeAlD
Hydroflumethiazide—Thrombocytopenia—Dactinomycin—skin cancer	0.00269	0.00742	CcSEcCtD
Hydroflumethiazide—Vomiting—Imiquimod—skin cancer	0.00264	0.00727	CcSEcCtD
Hydroflumethiazide—Anorexia—Dactinomycin—skin cancer	0.00262	0.00722	CcSEcCtD
Hydroflumethiazide—Rash—Imiquimod—skin cancer	0.00262	0.00721	CcSEcCtD
Hydroflumethiazide—Dermatitis—Imiquimod—skin cancer	0.00262	0.00721	CcSEcCtD
Hydroflumethiazide—Headache—Imiquimod—skin cancer	0.0026	0.00717	CcSEcCtD
Hydroflumethiazide—Decreased appetite—Bleomycin—skin cancer	0.00256	0.00706	CcSEcCtD
Hydroflumethiazide—Jaundice—Docetaxel—skin cancer	0.00253	0.00697	CcSEcCtD
Hydroflumethiazide—Leukopenia—Fluorouracil—skin cancer	0.00251	0.00693	CcSEcCtD
Hydroflumethiazide—CA4—lymph node—skin cancer	0.00249	0.00665	CbGeAlD
Hydroflumethiazide—Nausea—Imiquimod—skin cancer	0.00247	0.00679	CcSEcCtD
Hydroflumethiazide—Thrombocytopenia—Temozolomide—skin cancer	0.00244	0.00671	CcSEcCtD
Hydroflumethiazide—Agranulocytosis—Docetaxel—skin cancer	0.00242	0.00667	CcSEcCtD
Hydroflumethiazide—Decreased appetite—Dactinomycin—skin cancer	0.00239	0.00659	CcSEcCtD
Hydroflumethiazide—Anorexia—Temozolomide—skin cancer	0.00237	0.00653	CcSEcCtD
Hydroflumethiazide—CA9—HIF-1-alpha transcription factor network—TERT—skin cancer	0.00237	0.00904	CbGpPWpGaD
Hydroflumethiazide—Urticaria—Bleomycin—skin cancer	0.00234	0.00646	CcSEcCtD
Hydroflumethiazide—Thrombocytopenia—Fluorouracil—skin cancer	0.00225	0.00618	CcSEcCtD
Hydroflumethiazide—Anorexia—Fluorouracil—skin cancer	0.00219	0.00602	CcSEcCtD
Hydroflumethiazide—Hypersensitivity—Bleomycin—skin cancer	0.00217	0.00599	CcSEcCtD
Hydroflumethiazide—Decreased appetite—Temozolomide—skin cancer	0.00216	0.00596	CcSEcCtD
Hydroflumethiazide—Constipation—Temozolomide—skin cancer	0.00213	0.00586	CcSEcCtD
Hydroflumethiazide—Asthenia—Bleomycin—skin cancer	0.00212	0.00583	CcSEcCtD
Hydroflumethiazide—CA2—lymph node—skin cancer	0.00207	0.00551	CbGeAlD
Hydroflumethiazide—Hypersensitivity—Dactinomycin—skin cancer	0.00203	0.00558	CcSEcCtD
Hydroflumethiazide—SLC12A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00202	0.0077	CbGpPWpGaD
Hydroflumethiazide—Decreased appetite—Fluorouracil—skin cancer	0.00199	0.00549	CcSEcCtD
Hydroflumethiazide—Urticaria—Temozolomide—skin cancer	0.00198	0.00545	CcSEcCtD
Hydroflumethiazide—Asthenia—Dactinomycin—skin cancer	0.00197	0.00544	CcSEcCtD
Hydroflumethiazide—Muscle spasms—Docetaxel—skin cancer	0.00195	0.00537	CcSEcCtD
Hydroflumethiazide—Diarrhoea—Dactinomycin—skin cancer	0.00188	0.00519	CcSEcCtD
Hydroflumethiazide—Vomiting—Bleomycin—skin cancer	0.00188	0.00517	CcSEcCtD
Hydroflumethiazide—Rash—Bleomycin—skin cancer	0.00186	0.00512	CcSEcCtD
Hydroflumethiazide—Dermatitis—Bleomycin—skin cancer	0.00186	0.00512	CcSEcCtD
Hydroflumethiazide—Hypersensitivity—Temozolomide—skin cancer	0.00183	0.00505	CcSEcCtD
Hydroflumethiazide—SLC12A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00183	0.00699	CbGpPWpGaD
Hydroflumethiazide—ATP1A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00183	0.00699	CbGpPWpGaD
Hydroflumethiazide—Urticaria—Fluorouracil—skin cancer	0.00182	0.00502	CcSEcCtD
Hydroflumethiazide—Leukopenia—Docetaxel—skin cancer	0.00182	0.005	CcSEcCtD
Hydroflumethiazide—Asthenia—Temozolomide—skin cancer	0.00179	0.00492	CcSEcCtD
Hydroflumethiazide—Nausea—Bleomycin—skin cancer	0.00175	0.00483	CcSEcCtD
Hydroflumethiazide—Vomiting—Dactinomycin—skin cancer	0.00175	0.00482	CcSEcCtD
Hydroflumethiazide—Rash—Dactinomycin—skin cancer	0.00173	0.00478	CcSEcCtD
Hydroflumethiazide—Diarrhoea—Temozolomide—skin cancer	0.0017	0.00469	CcSEcCtD
Hydroflumethiazide—Hypersensitivity—Fluorouracil—skin cancer	0.00169	0.00465	CcSEcCtD
Hydroflumethiazide—Dizziness—Temozolomide—skin cancer	0.00165	0.00453	CcSEcCtD
Hydroflumethiazide—Nausea—Dactinomycin—skin cancer	0.00163	0.0045	CcSEcCtD
Hydroflumethiazide—Thrombocytopenia—Docetaxel—skin cancer	0.00162	0.00446	CcSEcCtD
Hydroflumethiazide—Vomiting—Temozolomide—skin cancer	0.00158	0.00436	CcSEcCtD
Hydroflumethiazide—Anorexia—Docetaxel—skin cancer	0.00158	0.00435	CcSEcCtD
Hydroflumethiazide—Rash—Temozolomide—skin cancer	0.00157	0.00432	CcSEcCtD
Hydroflumethiazide—Diarrhoea—Fluorouracil—skin cancer	0.00157	0.00432	CcSEcCtD
Hydroflumethiazide—Dermatitis—Temozolomide—skin cancer	0.00157	0.00432	CcSEcCtD
Hydroflumethiazide—Headache—Temozolomide—skin cancer	0.00156	0.00429	CcSEcCtD
Hydroflumethiazide—CA1—C-MYB transcription factor network—CDKN2A—skin cancer	0.00152	0.0058	CbGpPWpGaD
Hydroflumethiazide—Dizziness—Fluorouracil—skin cancer	0.00152	0.00418	CcSEcCtD
Hydroflumethiazide—Nausea—Temozolomide—skin cancer	0.00148	0.00407	CcSEcCtD
Hydroflumethiazide—Vomiting—Fluorouracil—skin cancer	0.00146	0.00402	CcSEcCtD
Hydroflumethiazide—Rash—Fluorouracil—skin cancer	0.00145	0.00398	CcSEcCtD
Hydroflumethiazide—Dermatitis—Fluorouracil—skin cancer	0.00144	0.00398	CcSEcCtD
Hydroflumethiazide—Decreased appetite—Docetaxel—skin cancer	0.00144	0.00396	CcSEcCtD
Hydroflumethiazide—Headache—Fluorouracil—skin cancer	0.00144	0.00396	CcSEcCtD
Hydroflumethiazide—CA1—C-MYB transcription factor network—PTGS2—skin cancer	0.00142	0.00543	CbGpPWpGaD
Hydroflumethiazide—Constipation—Docetaxel—skin cancer	0.00142	0.0039	CcSEcCtD
Hydroflumethiazide—Nausea—Fluorouracil—skin cancer	0.00136	0.00375	CcSEcCtD
Hydroflumethiazide—Hypersensitivity—Docetaxel—skin cancer	0.00122	0.00336	CcSEcCtD
Hydroflumethiazide—Asthenia—Docetaxel—skin cancer	0.00119	0.00327	CcSEcCtD
Hydroflumethiazide—KCNMA1—Circadian rythm related genes—CDK4—skin cancer	0.00118	0.00452	CbGpPWpGaD
Hydroflumethiazide—CA14—Metabolism—PLIN2—skin cancer	0.00116	0.00444	CbGpPWpGaD
Hydroflumethiazide—Diarrhoea—Docetaxel—skin cancer	0.00113	0.00312	CcSEcCtD
Hydroflumethiazide—CA1—C-MYB transcription factor network—NRAS—skin cancer	0.00111	0.00422	CbGpPWpGaD
Hydroflumethiazide—Dizziness—Docetaxel—skin cancer	0.00109	0.00301	CcSEcCtD
Hydroflumethiazide—CA5B—Metabolism—PLIN2—skin cancer	0.00106	0.00404	CbGpPWpGaD
Hydroflumethiazide—CA7—Metabolism—PLIN2—skin cancer	0.00106	0.00404	CbGpPWpGaD
Hydroflumethiazide—Vomiting—Docetaxel—skin cancer	0.00105	0.0029	CcSEcCtD
Hydroflumethiazide—Rash—Docetaxel—skin cancer	0.00104	0.00287	CcSEcCtD
Hydroflumethiazide—Dermatitis—Docetaxel—skin cancer	0.00104	0.00287	CcSEcCtD
Hydroflumethiazide—Headache—Docetaxel—skin cancer	0.00104	0.00286	CcSEcCtD
Hydroflumethiazide—Nausea—Docetaxel—skin cancer	0.000983	0.00271	CcSEcCtD
Hydroflumethiazide—CA12—Metabolism—PLIN2—skin cancer	0.000979	0.00374	CbGpPWpGaD
Hydroflumethiazide—CA1—C-MYB transcription factor network—KRAS—skin cancer	0.000951	0.00363	CbGpPWpGaD
Hydroflumethiazide—CA14—Metabolism—CSPG4—skin cancer	0.000936	0.00358	CbGpPWpGaD
Hydroflumethiazide—CA7—Metabolism—CSPG4—skin cancer	0.000852	0.00325	CbGpPWpGaD
Hydroflumethiazide—CA5B—Metabolism—CSPG4—skin cancer	0.000852	0.00325	CbGpPWpGaD
Hydroflumethiazide—CA1—C-MYB transcription factor network—HRAS—skin cancer	0.000809	0.00309	CbGpPWpGaD
Hydroflumethiazide—KCNMA1—Neuronal System—BRAF—skin cancer	0.000805	0.00307	CbGpPWpGaD
Hydroflumethiazide—CA12—Metabolism—CSPG4—skin cancer	0.000789	0.00301	CbGpPWpGaD
Hydroflumethiazide—CA4—Metabolism—PLIN2—skin cancer	0.000781	0.00298	CbGpPWpGaD
Hydroflumethiazide—CA2—Metabolism—PLIN2—skin cancer	0.000749	0.00286	CbGpPWpGaD
Hydroflumethiazide—CA1—Metabolism—PLIN2—skin cancer	0.000718	0.00274	CbGpPWpGaD
Hydroflumethiazide—CA9—Cellular responses to stress—CDK4—skin cancer	0.000699	0.00267	CbGpPWpGaD
Hydroflumethiazide—CA14—Metabolism—ENO2—skin cancer	0.000636	0.00243	CbGpPWpGaD
Hydroflumethiazide—CA9—Metabolism—PLIN2—skin cancer	0.000631	0.00241	CbGpPWpGaD
Hydroflumethiazide—CA4—Metabolism—CSPG4—skin cancer	0.000629	0.0024	CbGpPWpGaD
Hydroflumethiazide—CA2—Metabolism—CSPG4—skin cancer	0.000603	0.0023	CbGpPWpGaD
Hydroflumethiazide—CA7—Metabolism—ENO2—skin cancer	0.000579	0.00221	CbGpPWpGaD
Hydroflumethiazide—CA5B—Metabolism—ENO2—skin cancer	0.000579	0.00221	CbGpPWpGaD
Hydroflumethiazide—CA1—Metabolism—CSPG4—skin cancer	0.000578	0.00221	CbGpPWpGaD
Hydroflumethiazide—CA12—Metabolism—ENO2—skin cancer	0.000536	0.00205	CbGpPWpGaD
Hydroflumethiazide—CA9—Cellular responses to stress—CDKN2A—skin cancer	0.000534	0.00204	CbGpPWpGaD
Hydroflumethiazide—CA9—Metabolism—CSPG4—skin cancer	0.000509	0.00194	CbGpPWpGaD
Hydroflumethiazide—KCNMA1—Circadian rythm related genes—TP53—skin cancer	0.000503	0.00192	CbGpPWpGaD
Hydroflumethiazide—KCNMA1—Circadian rythm related genes—IL6—skin cancer	0.00046	0.00176	CbGpPWpGaD
Hydroflumethiazide—CA4—Metabolism—ENO2—skin cancer	0.000428	0.00163	CbGpPWpGaD
Hydroflumethiazide—CA2—Metabolism—ENO2—skin cancer	0.00041	0.00157	CbGpPWpGaD
Hydroflumethiazide—CA1—Metabolism—ENO2—skin cancer	0.000393	0.0015	CbGpPWpGaD
Hydroflumethiazide—KCNMA1—Neuronal System—HRAS—skin cancer	0.00037	0.00141	CbGpPWpGaD
Hydroflumethiazide—CA14—Metabolism—ERCC2—skin cancer	0.00037	0.00141	CbGpPWpGaD
Hydroflumethiazide—CA9—Metabolism—ENO2—skin cancer	0.000346	0.00132	CbGpPWpGaD
Hydroflumethiazide—CA5B—Metabolism—ERCC2—skin cancer	0.000336	0.00128	CbGpPWpGaD
Hydroflumethiazide—CA7—Metabolism—ERCC2—skin cancer	0.000336	0.00128	CbGpPWpGaD
Hydroflumethiazide—KCNMA1—Hemostasis—NRAS—skin cancer	0.000314	0.0012	CbGpPWpGaD
Hydroflumethiazide—CA12—Metabolism—ERCC2—skin cancer	0.000312	0.00119	CbGpPWpGaD
Hydroflumethiazide—CA9—Cellular responses to stress—TP53—skin cancer	0.000297	0.00114	CbGpPWpGaD
Hydroflumethiazide—CA9—Cellular responses to stress—IL6—skin cancer	0.000272	0.00104	CbGpPWpGaD
Hydroflumethiazide—KCNMA1—Hemostasis—KRAS—skin cancer	0.00027	0.00103	CbGpPWpGaD
Hydroflumethiazide—CA4—Metabolism—ERCC2—skin cancer	0.000248	0.000949	CbGpPWpGaD
Hydroflumethiazide—KCNMA1—Hemostasis—TP53—skin cancer	0.00024	0.000918	CbGpPWpGaD
Hydroflumethiazide—CA2—Metabolism—ERCC2—skin cancer	0.000238	0.00091	CbGpPWpGaD
Hydroflumethiazide—KCNMA1—Hemostasis—HRAS—skin cancer	0.00023	0.000878	CbGpPWpGaD
Hydroflumethiazide—CA1—Metabolism—ERCC2—skin cancer	0.000228	0.000872	CbGpPWpGaD
Hydroflumethiazide—CA14—Metabolism—PTGS2—skin cancer	0.000222	0.000846	CbGpPWpGaD
Hydroflumethiazide—CA5B—Metabolism—PTGS2—skin cancer	0.000202	0.00077	CbGpPWpGaD
Hydroflumethiazide—CA7—Metabolism—PTGS2—skin cancer	0.000202	0.00077	CbGpPWpGaD
Hydroflumethiazide—CA9—Metabolism—ERCC2—skin cancer	0.000201	0.000767	CbGpPWpGaD
Hydroflumethiazide—CA12—Metabolism—PTGS2—skin cancer	0.000187	0.000713	CbGpPWpGaD
Hydroflumethiazide—CA4—Metabolism—PTGS2—skin cancer	0.000149	0.000569	CbGpPWpGaD
Hydroflumethiazide—CA2—Metabolism—PTGS2—skin cancer	0.000143	0.000545	CbGpPWpGaD
Hydroflumethiazide—CA1—Metabolism—PTGS2—skin cancer	0.000137	0.000523	CbGpPWpGaD
Hydroflumethiazide—CA9—Metabolism—PTGS2—skin cancer	0.00012	0.00046	CbGpPWpGaD
